Gianluigi Savarese1, Åsa Jonsson2, Ann-Charlotte Hallberg3, Ulf Dahlström4, Magnus Edner1, Lars H Lund5. 1. Cardiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden. 2. Department of Medicine, Division of Cardiology, County Hospital Ryhov, Jönköping, Sweden. 3. Department of Computer and Information Science, Linköping University, Linköping, Sweden. 4. Department of Cardiology and Department of Medical and Health Sciences, Linköping University, Linköping, Sweden. 5. Cardiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden; Heart and Vascular Theme, Karolinska University Hospital, Stockholm, Sweden. Electronic address: lars.lund@alumni.duke.edu.
Abstract
BACKGROUND: The role of anemia in heart failure with mid-range and preserved ejection fraction (HFmrEF, EF 40-49% and HFpEF, EF ≥50%) is unknown. We aimed to compare prevalence of, associations with, and prognostic role of anemia in HF across the EF spectrum. METHODS: In patients from the Swedish HF Registry, we assessed the associations between clinical characteristics and anemia (hemoglobin <120 g/L in women and <130 g/L in men) by multivariable logistic regression, and between anemia, composite of all-cause death and HF hospitalization and all-cause death alone by multivariable Cox regression. RESULTS: Of 49,985 patients with HF (anemia = 34%), 23% had HFpEF (anemia = 41%), 21% had HFmrEF (anemia = 35%) and 55% had HFpEF (anemia = 32%). Higher EF was independently associated with higher likelihood of concomitant anemia. Important predictors of anemia across the EF spectrum were male sex, older age, worse New York Heart Association class and renal function, lower systolic blood pressure, higher N-Terminal B-type natriuretic peptides levels, diabetes, valvular disease and in-patient status. Anemia had adjusted hazard ratios (95% CI) for mortality or HF hospitalization 1.24 (1.18-1.30) in HFpEF, 1.26 (1.19-1.34) in HFmrEF and 1.14 (1.10-1.19) in HFrEF; pinteractionEF = 0.003; and for mortality 1.28 (1.20-1.36) in HFpEF, 1.21 (1.13-1.29) in HFmrEF, and 1.30 (1.24-1.35) in HFrEF; pinteractionEF = 0.22. CONCLUSIONS: In this nation-wide registry, prevalence of anemia was higher in HFpEF vs. HFmrEF vs. HFrEF, but was associated with a similarly increased risk of death across the EF spectrum, with greater risk of death or HF hospitalization in HFpEF and HFmrEF vs. HFrEF.
BACKGROUND: The role of anemia in heart failure with mid-range and preserved ejection fraction (HFmrEF, EF 40-49% and HFpEF, EF ≥50%) is unknown. We aimed to compare prevalence of, associations with, and prognostic role of anemia in HF across the EF spectrum. METHODS: In patients from the Swedish HF Registry, we assessed the associations between clinical characteristics and anemia (hemoglobin <120 g/L in women and <130 g/L in men) by multivariable logistic regression, and between anemia, composite of all-cause death and HF hospitalization and all-cause death alone by multivariable Cox regression. RESULTS: Of 49,985 patients with HF (anemia = 34%), 23% had HFpEF (anemia = 41%), 21% had HFmrEF (anemia = 35%) and 55% had HFpEF (anemia = 32%). Higher EF was independently associated with higher likelihood of concomitant anemia. Important predictors of anemia across the EF spectrum were male sex, older age, worse New York Heart Association class and renal function, lower systolic blood pressure, higher N-Terminal B-type natriuretic peptides levels, diabetes, valvular disease and in-patient status. Anemia had adjusted hazard ratios (95% CI) for mortality or HF hospitalization 1.24 (1.18-1.30) in HFpEF, 1.26 (1.19-1.34) in HFmrEF and 1.14 (1.10-1.19) in HFrEF; pinteractionEF = 0.003; and for mortality 1.28 (1.20-1.36) in HFpEF, 1.21 (1.13-1.29) in HFmrEF, and 1.30 (1.24-1.35) in HFrEF; pinteractionEF = 0.22. CONCLUSIONS: In this nation-wide registry, prevalence of anemia was higher in HFpEF vs. HFmrEF vs. HFrEF, but was associated with a similarly increased risk of death across the EF spectrum, with greater risk of death or HF hospitalization in HFpEF and HFmrEF vs. HFrEF.
Authors: Mir Abdul Qadir; Nadeem Rashid; Mohummad Alam Mengal; Muhammad Sharif Hasni; Shahab Ud Din Kakar; Ghulam Mustafa Khan; Nisar Ahmed Shawani; Imran Ali; Irfan Shahzad Sheikh; Nasimullah Khan Journal: Biomed Res Int Date: 2022-02-09 Impact factor: 3.411
Authors: Anita Pintér; Anett Behon; Boglárka Veres; Eperke Dóra Merkel; Walter Richard Schwertner; Luca Katalin Kuthi; Richard Masszi; Bálint Károly Lakatos; Attila Kovács; Dávid Becker; Béla Merkely; Annamária Kosztin Journal: Diagnostics (Basel) Date: 2022-02-17